Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19430234 | 0.98 | GBA1 (0.48) | GBA1PRMT6KDM5BRAB9AEZH2 | |
| SCHEMBL19430406 | 0.91 | GBA1 (0.46) | GBA1PRMT6KDM5BRAB9AEZH2 | |
| SCHEMBL19421634 | 0.90 | GBA1 (0.50) | GBA1KDM5BRAB9AEZH2POLB | |
| SCHEMBL19429861 | 0.90 | HPGD (0.46) | GBA1PRMT6KDM5BKDM4E | |
| SCHEMBL19429971 | 0.90 | GBA1 (0.44) | GBA1PRMT6KDM5BRAB9AEZH2 | |
| SCHEMBL19421563 | 0.88 | GBA1 (0.49) | GBA1KDM5BRAB9AEZH2POLB | |
| SCHEMBL19430272 | 0.86 | KDM5B (0.48) | PRMT6KDM5BRAB9AEZH2 | |
| SCHEMBL19430024 | 0.86 | PRMT6 (0.43) | GBA1PRMT6KDM5BRAB9AEZH2 | |
| SCHEMBL19430008 | 0.86 | KDM5B (0.44) | GBA1PRMT6KDM5BRAB9AEZH2 | |
| SCHEMBL17606388 | 0.84 | NTRK1 (0.46) | GBA1PRMT6KDM5BRAB9AEZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | GBA1 2736/4885PRMT6 4/4885KDM5B 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.